文献速递消化系统肿瘤

可切除肝癌合并门静脉癌栓的新辅助三维适形放疗随机对照研究

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.
PubMed 文献 · J Clin Oncol · 2019-07-08

新辅助放疗组6、12、18、24个月总生存率分别为89.0%、75.2%、43.9%、27.4%,优于单纯手术组的81.7%、43.1%、16.7%、9.4%(P < .001)。IL-6表达升高与放疗抵抗相关。

要点

  • 新辅助放疗组20.7%患者达部分缓解(mRECIST标准)。
  • 新辅助放疗显著改善总生存和无病生存,多因素分析示死亡风险比0.35。
  • 放疗前血清及肿瘤组织IL-6升高与放疗抵抗相关。

核心结论

  • 对可切除肝细胞癌合并门静脉癌栓患者,新辅助放疗后肝切除较单纯肝切除显著改善术后生存结局。
  • IL-6可能预测该类患者对放疗的反应。

研究设计与样本

  • 2016年1月至2017年12月开展的多中心随机开放标签对照研究。
  • 纳入可切除肝细胞癌合并门静脉癌栓患者,随机分为新辅助放疗后肝切除组(n = 82)和单纯肝切除组(n = 82)。
  • 主要终点为总生存,采用mRECIST评估放疗疗效。

主要发现

  • 新辅助放疗组17例(20.7%)达部分缓解。
  • 新辅助放疗组6、12、18、24个月总生存率分别为89.0%、75.2%、43.9%、27.4%,单纯手术组为81.7%、43.1%、16.7%、9.4%(P < .001)。
  • 新辅助放疗组对应无病生存率为56.9%、33.0%、20.3%、13.3%,单纯手术组为42.1%、14.9%、5.0%、3.3%(P < .001)。
  • 多因素Cox回归示新辅助放疗降低肝癌相关死亡(HR 0.35,95%CI 0.23~0.54,P < .001)和复发(HR 0.45,95%CI 0.31~0.64,P < .001)。
  • 放疗前血清及肿瘤组织IL-6表达升高与放疗抵抗显著相关。

关键数值与推荐

  • 总生存率:新辅助放疗组6/12/18/24个月为89.0%/75.2%/43.9%/27.4%,单纯手术组为81.7%/43.1%/16.7%/9.4%(P < .001)。
  • 无病生存率:新辅助放疗组6/12/18/24个月为56.9%/33.0%/20.3%/13.3%,单纯手术组为42.1%/14.9%/5.0%/3.3%(P < .001)。
  • 肝癌相关死亡HR 0.35(95%CI 0.23~0.54,P < .001),复发HR 0.45(95%CI 0.31~0.64,P < .001)。

临床怎么用

  • 对可切除肝细胞癌合并门静脉癌栓患者,可考虑新辅助三维适形放疗后行肝切除以改善生存。
  • 治疗决策前可参考IL-6表达水平评估放疗抵抗风险。

局限性

  • 开放标签设计可能引入偏倚。
  • 研究仅纳入可切除肝细胞癌合并门静脉癌栓患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the survival outcomes of neoadjuvant three-dimensional conformal radiotherapy (RT) followed by hepatectomy with hepatectomy alone in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT). PATIENTS AND METHODS: A randomized, multicenter controlled study was conducted from January 2016 to December 2017 in patients with resectable HCC and PVTT. Patients were randomly assigned to receive neoadjuvant RT followed by hepatectomy (n = 82) or hepatectomy alone (n = 82). The modified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines were used to evaluate the therapeutic effects of RT. The primary end point was overall survival. The expression of interleukin-6 (IL-6) in patients' serum before RT and in surgical specimens was correlated with response to RT. RESULTS: In the neoadjuvant RT group, 17 patients (20.7%) had partial remission. The overall survival rates for the neoadjuvant RT group at 6, 12, 18, and 24 months were 89.0%, 75.2%, 43.9%, and 27.4%, respectively, compared with 81.7%, 43.1%, 16.7%, and 9.4% in the surgery-alone group (P < .001). The corresponding disease-free survival rates were 56.9%, 33.0%, 20.3%, and 13.3% versus 42.1%, 14.9%, 5.0%, and 3.3% (P < .001). On multivariable Cox regression analyses, neoadjuvant RT significantly reduced HCC-related mortality and HCC recurrence rates compared with surgery alone (hazard ratios, 0.35 [95% CI, 0.23 to 0.54; P < .001] and 0.45 [95% CI, 0.31 to 0.64; P < .001]). Increased expressions of IL-6 in pre-RT serum and tumor tissues were significantly associated with resistance to RT. CONCLUSION: For patients with resectable HCC and PVTT, neoadjuvant RT provided significantly better postoperative survival outcomes than surgery alone. IL-6 may predict response to RT in these patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wei X, Jiang Y, Zhang X, et al. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study. J Clin Oncol. 2019. PMID: 31283409. doi:10.1200/JCO.18.02184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。